The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...

BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.

Drug repositioning is an important approach for predicting new disease indications of the existing drugs in drug discovery. A great progress has been achieved in drug repositioning. However, ...

“The off-label use of Ozempic among non-diabetic patients has led to a shortage for those with type 2 diabetes and reduced efficacy due to the lower dose,” said Dr Rohana. She also highlighted studies ...